Tyrosine kinase inhibitors, such as gefitinib (Iressa ™, ZD1839), block the EGFR. As a result, there is inhibition of cellular proliferation, promotion of apoptosis, and inhibition of anti ...

ImClone Systems/Merck KGaA/Bristol-Myers Squibb), gefitinib (Iressa; AstraZeneca) and erlotinib (Tarceva; OSI Pharmaceuticals/ Genentech/Roche) provide the potential for physicians to try an ...

The majority of people with advanced EGFR-mutant non-small cell lung cancer (NSCLC) receiving first-line osimertinib ...

The crackdown comes after years of efforts to boost China sales by AstraZeneca, which is widely seen in the pharmaceutical industry as the most successful at navigating Beijing’s abrupt regulatory ...

The same situation now exists for the roughly 10-15 per cent of Non-Small Cell Lung Cancer (NSCLC) patients with a specific EGFR mutation; physicians now have the choice of Iressa, Tarceva ...

like AstraZeneca's market-leading Tagrisso (osimertinib), AZ’s older Iressa (gefitinib) and Roche’s Tarceva (erlotinib). Over time. most targeted cancer drugs have their efficacy limited by ...

We have summarized in this article the current state of combination therapy of approved targeted drugs and irradiation. Since the introduction of the first targeted compounds almost (trastuzumab ...

While there he was responsible for the biology of the project that produced the EGFR kinase inhibitor gefitinib (Iressa) that has received regulatory approval in non small cell lung cancer and was one ...